ViroGates Unveils suPARnostic® TurbiLatex with Roche Diagnostics

Tue Aug 20 2019

ViroGates has finished developing and getting regulatory approval for its suPARnostic TurbiLatex product, using turbidimetric technology.

Initially cleared for the Roche Diagnostics cobas C 111 analyzer, this is a pivotal move, as Roche dominates clinical chemistry in European hospital markets with its cobas platforms.

The launch on cobas C 111 is the first step. Next, they aim to validate it on higher-throughput instruments like the cobas c 500 and c 700 series widely used in diagnostic labs.

The suPARnostic TurbiLatex automates blood sample handling at central labs. This means medical professionals can get suPAR measurements concurrently with other diagnostic data, streamlining decision-making.

The TurbiLatex product, rooted in turbidimetry, gauges the loss of transmitted light intensity due to particles in blood samples. This technique is crucial for immunoassays and forms the basis of nearly all central lab clinical chemistry instruments in hospitals.

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of four products:

suPARnostic POC+

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates